Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: Improvement following anti-tumor necrosis factor-α antibody therapy

Blood

Volumn 100, Issue 2, 2002, Pages 474-482

  Papadaki, Helen A ^a,b   Kritikos, Heraklis D ^a   Valatas, Vasilis ^a   Boumpas, Dimitrios T ^a   Eliopoulos, George D ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD36 ANTIGEN; CD71 ANTIGEN; GLYCOPHORIN A; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ANEMIA; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; BURST FORMING UNIT E; CHRONIC DISEASE; CLINICAL ARTICLE; CONVALESCENCE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ERYTHROID CELL; ERYTHROPOIESIS; FEMALE; HEMOGLOBIN ANALYSIS; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS;

EID: 0037100511     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0136     Document Type: Article

References (48)

1. Cytokine pathways and joint inflammation in rheumatoid arthritis
2. Rheumatoid arthritis
3. Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis: Relationship to serum levels of hyaluronan and antigenic keratan sulfate
4. Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease
5. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: Evidence for a tumor necrosis factor alpha (TNFα)-mediated effect
6. Anti-tumor necrosis factor ameliorates joint diseases in murine collagen-induced arthritis
7. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis (cA2) versus placebo in rheumatoid arthritis
8. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
9. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
10. Infliximab and methotrexate in the treatment of rheumatoid arthritis
11. Anaemia of chronic disease in rheumatoid arthritis: In vivo effects of tumour necrosis factor alpha blockade
12. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
13. Activity indices in rheumatoid arthritis
14. Decreased erythropoietin response in patients with anemia of cancer
15. Anaemia of chronic disease: Diagnostic significance of erythrocyte and serological parameters in iron deficient rheumatoid arthritis patients
16. Clonal and long-term cultures using human bone marrow
17. Differentiation and proliferation of hemopoietic cells in culture
18. The hematopoietic defect in aplastic anemia assessed by long-term marrow culture
19. The maintenance of hemopoietic stem cells in human long-term marrow culture
20. The use of 7-amino actinomycin D in identifying apoptosis: Simplicity of use and broad spectrum of application compared with other techniques
21. Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure
22. Flow cytometric analysis of human bone marrow, I: Normal erythroid development
23. Membrane glycoprotein CD36: A review of its roles in adherence, signal transduction, and transfusion medicine
24. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis
25. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2
26. Inadequate erythropoietin response to anemia: Definition and clinical relevance
27. Progress in understanding the pathogenesis of the anemia of chronic disease
28. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor
29. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice
30. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: Role of p55 and p75 TNF receptors
31. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon
32. Peripheral blood mononuclear cells from patients with rheumatoid arthritis suppress erythropoiesis in vitro via the production of tumor necrosis factor alpha
33. Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis
34. Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis
35. The pathogenesis of anemia in rheumatoid arthritis: A clinical and laboratory analysis
36. Introduction to the hematopoietic system
37. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis
38. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis
39. + cells of patients with aplastic anaemia
40. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis
41. Availability of iron and degree of inflammation modifies the response to recombinant human erythropoietin when treating anemia of chronic disease in patients with rheumatoid arthritis
42. Serum erythropoietin in rheumatoid arthritis and other inflammatory arthritides: Relationship to anaemia and the effect of anti-inflammatory anaemia and the effect of anti-inflammatory treatment
43. Assessment of antibodies to doublestranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebocontrolled trials
44. Interleukin-6-associated anemia: Determination of the underlying mechanism
45. Anaemia of chronic disease in rheumatoid arthritis: Raised serum interleukin-6 (IL-6) levels and effects of IL-6 and anti-IL-6 on in vitro erythropoiesis
46. Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system
47. The hematological effects of folate analogs: Implications for using the dihydrofolate reductase gene for in vivo selection
48. The hierarchy of quality-of-life assessment, the Health Assessment Questionnaire (HAQ), and issues mandating development of a toxicity index